RedHill Biopharma Ltd.’s Term Loan Facility

Cravath represented the borrower, RedHill Biopharma Inc., a wholly‑owned subsidiary of RedHill Biopharma Ltd., in connection with the arrangement of its $115 million term loan facility provided by HCR Collateral Management, LLC. RedHill Biopharma Ltd., an Israeli company, is a specialty biopharmaceutical company that focuses on the development and commercialization of clinical late-stage drugs for the treatment of gastrointestinal diseases in the United States. The transaction closed on February 23, 2020.

The Cravath team included partner Nicholas A. Dorsey and associates Benjamin G. Joseloff and Darien Pun on banking matters, partner David J. Kappos and associate Somi A. Umolu on intellectual property matters, and partner J. Leonard Teti II and associates Arvind Ravichandran and Kyle R. Jorstad on tax matters. Stuti Sarin also worked on banking matters.